Clinical Trial Update: A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated the safety, efficacy, pharmacokinetics, and pharmacodynamics of M281 administered to pregnant women at high risk for early-onset Hemol…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemolytic Disease of the Fetus and Newborn

Drugs mentioned

• M281

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Hemolytic Disease of the Fetus and Newborn | Phase 2 | Status: COMPLETED | Results posted: 2026-01-28